Natera plans to launch its clinical oncology and transplantation tests next year and is hopeful that guidelines endorsing NIPT for average-risk pregnancies are imminent.
The platform, which Waters introduced last month, uses flow-injection tandem mass spectrometry to enable high-throughput analysis of dried blood spots.
Androvia LifeSciences has developed a predictive biomarker test that some clinicians are using to determine a man's fertility.
During the first year of the TRIDENT-2 study, 74,000 women opted for NIPT, which was switched from in-house-developed platforms to Illumina's VeriSeq in May of this year.
Asuragen's technology will be used in the Early Check study to identify children with rare health conditions, such as fragile X syndrome, before symptoms appear.
Regenerative therapeutics company StemCyte will offer Fulgent's Beacon Expanded Carrier Screening and Newborn Genetic Analysis testing services.
The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.
The so-called enVision HPV test performed well in a comparison to Roche's Cobas HPV assay, and the Singapore researchers are considering other test applications.
The assets include significant genetic data related to women's diseases and degenerative disc disease, which Predictive will use to develop gene-based diagnostics.
The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.
The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.
ReproSource provides services such as ovarian health and recurrent pregnancy loss assessments, as well as implantation failure and semen quality.
The test detects nine organisms considered to be common causes of endometritis, a condition for which no commercial molecular tests are available.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
The test could someday be used to recommend lifestyle changes in otherwise low-risk women who are on the path to becoming diabetic during pregnancy.
Although the two studies seem to provide conflicting results on the impact of PGS, the "devil's in the details," according to an outside expert.
In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The firm is working on harnessing its ability to assess fetal fraction to develop new methods to predict fetal aneuploidy risks and pregnancy complications.
A manufacturing defect caused the control line on the affected tests to not display, which can cause test results to be misinterpreted as negative for the presence of amniotic fluid.